Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
MWN-AI** Summary
Pierre Fabre Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has accepted their Biologics License Application (BLA) for tabelecleucel, designed for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). This therapy, noted for being the first allogeneic T-cell treatment for this severe condition, is under Priority Review, offering a glimmer of hope to patients facing limited treatment options and an alarming prognosis—often only weeks to months of survival post-treatment failure.
EBV+ PTLD is a rare and potentially fatal malignancy that can develop after hematopoietic cell or solid organ transplants when the immune system is suppressed. Tabelecleucel stands out as an off-the-shelf, EBV-specific T-cell immunotherapy that targets and destroys cells infected with the virus. With a Prescription Drug User Fee Act (PDUFA) action date set for January 10, 2026, successful approval could mark a pivotal moment in U.S. healthcare for patients affected by this aggressive disease.
This submission follows Atara Biotherapeutics’ resubmission of the BLA on July 11, which was addressed to resolve certain manufacturing facility observations from a prior review. The extensive BLA includes data from over 430 patients, further validated by ongoing trials assessing the drug's efficacy.
While approved in Europe and the UK under the brand name EBVALLO™, the FDA's review represents another significant step for Pierre Fabre, which has taken on global responsibilities for manufacturing and clinical supply of tabelecleucel. The company is focused on providing innovative therapies in oncology and rare diseases, reinforcing its commitment to enhancing patient outcomes worldwide.
MWN-AI** Analysis
The recent announcement from Pierre Fabre Pharmaceuticals Inc. regarding the FDA's acceptance and priority review of the BLA for Tabelecleucel marks a pivotal moment for the company and investors alike. Tabelecleucel represents the first allogeneic T-cell therapy for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), a condition characterized by a dire lack of treatment options and a poor prognosis for patients.
From an investment perspective, this development is particularly promising. With a PDUFA target action date set for January 10, 2026, the potential approval of Tabelecleucel could place Pierre Fabre at the forefront of a niche but critical market. The absence of FDA-approved therapies for this indication indicates a potential first-mover advantage, which could drive significant revenue streams if successful. Given the high unmet medical need in the EBV+ PTLD space, the market could significantly reward PFP should Tabelecleucel receive approval.
Moreover, the strategic collaboration with Atara Biotherapeutics and the swift resolution of the manufacturing facility observations demonstrate agility and commitment to compliance and quality assurance—critical factors in the pharmaceutical industry. This capacity for rapid response could bolster investor confidence and reflect positively in stock performance.
It is also worth noting that the global responsibility for Tabelecleucel manufacturing assumed by PFP enhances their operational efficiency and market positioning. As they expand their product offerings within rare diseases and oncology, the company's diversified therapeutic pipeline—including treatments for melanoma and lung cancer—provides additional avenues for growth and indicates a robust long-term strategy.
Investors should consider the stock as a 'buy' on the basis of promising potential market opportunities linked to Tabelecleucel and the company's overall innovative trajectory in addressing pressing healthcare needs. Regular monitoring of FDA developments will be critical as the January 2026 date approaches.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment
EBV+ PTLD is an ultra-rare, acute, and potentially deadly blood malignancy that occurs after hematopoietic cell transplant (HCT) or solid organ transplant (SOT) when T-cell activity is impaired by immunosuppression
Tabelecleucel has a Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026 and would be the first approved therapy in the U.S. for EBV+ PTLD
SECAUCUS, N.J. , July 24, 2025 /PRNewswire/ -- Pierre Fabre Pharmaceuticals Inc. (PFP) announces the acceptance by U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) and Priority Review of tabelecleucel, indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.
Atara Biotherapeutics Inc. (Nasdaq: ATRA) resubmitted the tabelecleucel BLA on July 11 , having in collaboration with PFP, swiftly addressed the third-party manufacturing facility observations outlined in the January 2025 Complete Response Letter.
"Patients diagnosed with relapsed or refractory EBV+ PTLD have no approved FDA treatment options, and following failure of initial therapy their survival is unfortunately measured in only weeks to months. Today's BLA acceptance gives hope to these patients and is a significant step towards making this innovative cell therapy available in the United States ," said Adriana Herrera , Chief Executive Officer of PFP, the Pierre Fabre Laboratories Pharmaceutical subsidiary in the U.S. "We are now completely focused on preparing for potential FDA approval of this innovative new treatment option."
Tabelecleucel is an allogeneic, off the shelf, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells. The BLA includes data covering more than 430 patients treated with tabelecleucel including the ongoing pivotal ALLELE study investigating the therapy in adults and children two years of age and older with relapsed or refractory EBV+ PTLD following SOT or HCT.
Tabelecleucel was granted marketing authorization under the brand name EBVALLO™ in December 2022 by the European Commission (EC). Marketing authorization was also granted by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom in May 2023 and by Swissmedic in Switzerland in May 2024 .
Since March 31, 2025 , PFP has assumed global responsibility for tabelecleucel manufacturing of commercial product for European markets and for global clinical trial supply. On July 15, 2025 , Atara Biotherapeutics transferred the tabelecleucel Investigational New Drug Application to Pierre Fabre Medicament, a subsidiary of Pierre Fabre Laboratories. As per the terms of the restated exclusive worldwide licensing agreement between Atara and Pierre Fabre Laboratories announced in November 2023 , Atara is responsible for regulatory procedures up until BLA transfer to Pierre Fabre Pharmaceuticals.
About Pierre Fabre Pharmaceuticals and Pierre Fabre Laboratories
The mission of PFP is to deliver breakthrough therapies in oncology and rare diseases to patient populations with high unmet needs and limited treatment options. Our belief is that every time we care for a single person, we make the whole world better.
PFP is the US pharmaceutical subsidiary of Pierre Fabre Laboratories, a foundation-owned company with seven decades of impact. Pierre Fabre Laboratories is a global healthcare company, established in 43 countries, with over 10,000 employees, and with products distributed in 120 territories across the globe.
The Pierre Fabre Laboratories foundation ownership enhances the ability of the company to create long-term value for patients. Partnerships and acquisitions drive its innovative precision treatment pipeline and are enabled by the unique corporate structure.
Building on the legacy of Pierre Fabre Laboratories, innovation is the life blood of PFP, and patient experience drives everything the company does. PFP aspires to design and develop therapeutic solutions inspired by patients and healthcare professionals; draw on science and nature as perpetual sources of inspiration; develop long-term partnerships with researchers and innovators worldwide; and place pharmaceutical ethics and climate transition at the heart of our action.
Pierre Fabre Pharmaceuticals has therapies in development for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), NRAS-mutant melanoma, non-small cell lung cancer with mutation or amplification of MET, and X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Pierre Fabre Pharmaceuticals is headquartered in Secaucus, NJ .
For more information, visit www.pierrefabrepharmaceuticals.com , www.pierre-fabre.com , @Pierre Fabre Oncology.
SOURCE Pierre Fabre Pharmaceuticals
FAQ**
How does the collaboration with Atara Biotherapeutics Inc. (ATRA) influence the potential success of tabelecleucel's BLA application for treating EBV+ PTLD in the U.S. market?
What specific data from the ALLELE study supports the safety and efficacy of tabelecleucel, making it a promising treatment for EBV+ PTLD patients compared to current options?
In light of tabelecleucel's recent marketing authorizations in Europe, how might the global regulatory landscape impact its FDA approval timeline and market strategy for Pierre Fabre Pharmaceuticals Inc.?
Can you detail the long-term implications of the exclusive worldwide licensing agreement between Pierre Fabre Pharmaceuticals Inc. and Atara Biotherapeutics Inc. (ATRA) on future therapeutic developments for rare diseases?
**MWN-AI FAQ is based on asking OpenAI questions about Atara Biotherapeutics Inc. (NASDAQ: ATRA).
NASDAQ: ATRA
ATRA Trading
-6.29% G/L:
$5.96 Last:
58,004 Volume:
$6.41 Open:
